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Vincent D. Criscione1,2 and Martin A. Weinstock1,2
Over the past two decades, numerous efforts have been initiated to improve screening and early detection of
melanoma both in the United States and worldwide. It is commonly believed that these efforts have contributed
to the stabilization of melanoma mortality, and that the proportion of thick melanoma with unfavorable
prognosis is on the decline. Data obtained from 17 population-based cancer registries of the Surveillance
Epidemiology and End Result (SEER) program of the National Cancer Institute for 1988–2006 were used to
examine trends in melanoma tumor thickness. For malignant melanoma cases with recorded thickness, the
proportionate distribution among four thickness categories (p1, 1.01–2, 2.01–4, and44mm) remained relatively
stable over the 19-year study period, however, for melanomas resulting in death, the proportion of thick tumors
increased. The most substantial change occurred in the proportion of melanoma in situ, which nearly doubled
from 1988 to 2006. Surveillance and early detection efforts in the United States have not resulted in a substantial
reduction in the proportion of tumors with prognostically unfavorable thickness. Continued improvement and
new methods of screening, especially among demographics with higher incidence of thick tumors, is necessary.
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INTRODUCTION
Malignant melanoma remains one of the most rapidly
increasing cancers in the United States. In recent years, the
overall mortality has begun to stabilize, and rates have
declined among younger age groups (Linos et al., 2009).
Better secondary prevention efforts leading to improved
detection of early, thinner tumors with lower metastatic
potential are thought to be at least partially responsible.
Studies conducted in other countries have documented a
substantial rise in the proportion of thin tumors over the past
two decades (Garbe et al., 2000; Murray et al., 2005; Lipsker
et al., 2007; Tejera-Vaquerizo et al., 2008), but few reports
have detailed thickness trends in the United States (Dennis,
1999; Demierre et al., 2005; Linos et al., 2009), and only one
report directly commented on proportionate changes
(Demierre et al., 2005). We are unaware of previous reports
that document these trends for fatal melanomas. We used
population-based data from the Surveillance Epidemiology
and End Results (SEER) program of the National Cancer
Institute to examine the trends in tumor thickness for the
1988–2006 period.
RESULTS
A total of 153,124 malignant melanoma cases were identified
in 17 SEER registries between 1988 and 2006. Of these cases,
the majority was histologically classified as melanoma not
otherwise specified (47%), superficial spreading melanoma
(34%), nodular melanoma (7%) and lentigo maligna
melanoma (6%). The thickness was recorded for 85% of
cases. The majority of these cases (70%) had tumor thickness
p1mm (Table 1).
The proportion of malignant melanoma cases with
unknown thickness decreased from 1988–1993 to
2000–2006 (23 vs 13%, 95% confidence interval (CI) of
difference 10–12%). Of cases with recorded thickness, the
proportion of cases with thicknessp1mm increased from 68
to 71% between 1988–1993 and 2000–2006 (95% CI of
difference 2–4%). The proportion of cases with tumor
thickness 44mm also increased from 4.7 to 5.4% (95% CI
of difference 0.3–1%). Over the same time periods the
proportion of lesions with intermediate thickness (1.01–2mm
and 2.01–4mm) decreased from 17 to 15% (95% CI of
difference 2–3%) and 10 to 9% (95% CI of difference 1–2%),
respectively (Figure 1). Similar results were obtained when
only cases from the original 9 SEER registries for 1988–2006
were included in the analysis.
Among cases of malignant melanoma diagnosed in the 17
SEER registries between 1988 and 2006, 13,993 were
determined to be the primary cause of death on death
certificate review. Of these fatal melanomas, the majority
(54%) carried the histological diagnosis of melanoma not
otherwise specified. Nodular melanoma and superficial
spreading melanoma made up a similar proportion of fatal
cases (18 and 17%, respectively). Only 65% of fatal
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melanomas had a recorded tumor thickness. Cases with
recorded thickness had a fairly even distribution among the
four thickness categories (Table 1).
The proportion of fatal melanomas with unknown thick-
ness did not change significantly between 1988–1993 and
2000–2006 (36.33 vs 36.11; P¼0.83, 95% CI of difference
2 to 2%). For fatal melanomas with recorded thickness, the
proportion with thicknessp1mm decreased from 30 to 26%
between 1988–1993 and 2000–2006 (95% CI of difference
2–6%), whereas the proportion of fatal melanomas with
thickness 44mm increased from 16 to 27% between
1988–1993 and 2000–2006 (95% CI of difference 8–13%)
(Table 2). Similar results were obtained when nodular
melanoma cases were excluded from the analysis. There
were minimal changes in prognosis by thickness group during
the study period (Table 3).
The overall relative survival for melanoma (calculated
using study data) stabilizes at approximately 87.8% after
9 years. Hence, almost all deaths resulting from melanoma
diagnosed between 1988 and 1997 should have occurred by
2006. Among melanomas diagnosed between 1988 and 1997
with recorded thickness, the proportion of fatal melanomas
with thickness p1mm decreased from 30 to 27% between
1988–1992 and 1993–1997 (P¼0.026; 95% CI of difference
0.4–6.3%). The proportion of melanomas with thickness
44mm increased from 16 to 19% (P¼0.017; 95% CI of
difference 1–6%).
Median tumor thickness varied substantially with histolo-
gical type. Among the most common melanoma subtypes,
median thickness was greatest for nodular melanoma
(2.3mm), followed by acral melanoma (1.4mm), melanoma
not otherwise specified (0.6mm), superficial spreading
melanoma (0.6mm), and lentigo maligna melanoma
(0.4mm). Median tumor thickness for all cases of malignant
melanoma decreased from 0.66 to 0.60mm between
1988–1993 and 2000–2006. Median tumor thickness for fatal
melanomas increased from 1.8mm in 1988–1993 to 2.3mm
in 2000–2006 (Figure 2).
A total of 85,852 cases of melanoma in situ were reported
to the 17 SEER registries between 1988 and 2006. The
proportion of all melanomas that were in situ increased
substantially between 1988–1993 and 2000–2006 (25 vs
38%, 95% CI of difference 13–14%) (Figure 3).
Several inconsistencies were identified in the SEER data
regarding the coding of tumor thickness. Among cases of
melanoma in situ, 3,380 (3.4%) were coded as having tumor
thickness between 0.01 and 9.9mm. Of invasive malignant
melanoma cases, 1416 (1%) had a recorded tumor thickness
of 0 (no mass; no tumor observed). Of these, nearly half
(n¼654) were found to be the primary cause of death at
follow-up. An inquiry was made to SEER regarding these
inconsistencies.
DISCUSSION
Our analysis of more than 150,000 cases of malignant
melanoma demonstrates relatively stable proportions of thick
and thin melanoma in the United States over the past two
decades. This trend is consistent with our finding of only
minimal changes in median tumor thickness and results from
earlier population-based studies (Dennis, 1999; Demierre
et al., 2005; Linos et al., 2009). Our finding of increased
Table 1. Proportions of malignant melanoma
classified by tumor thickness, US 1988–2006
Tumor thickness Percentage No. of cases
Malignant melanomas (mm)
p1 70 91,174
1.01–2 16 20,424
2.01–4 9 11,702
44 5 6,894
Total 130,194
Fatal melanomas (mm)1
p1 27 2,472
1.01–2 23 2,142
2.01–4 27 2,474
44 22 2,041
Total 9,129
1Cases of malignant melanoma diagnosed between 1988 and 2006 with
melanoma recorded as primary cause of death on death certificate review.
Only cases with known thickness at diagnosis were included.
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Figure 1. Proportion of malignant melanomas by thickness: US 1988–2006.
Note: Only cases with known thickness are included.
Table 2. Trends in the proportion of fatal melanomas1
classified by tumor thickness, US 1988–2006
Percentage of tumors with known thickness
(no. of cases)
Percentage of
all tumors
Years p1mm 1.01–2mm 2.01–4mm 44mm Unknown
1988–1993 30 (649) 27 (579) 27 (579) 16 (352) 36 (1,232)
1994–1999 26 (759) 25 (738) 28 (809) 20 (597) 31 (1,333)
2000–2006 26 (1,064) 20 (825) 27 (1,086) 27 (1,092) 36 (2,299)
1Cases of malignant melanoma diagnosed between 1988 and 2006 with
melanoma recorded as primary cause of death on death certificate review.
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proportions of thick tumors among fatal melanomas after
2003 is probably due to deaths from thinner melanoma
diagnosed during the later years of the study occurring after
the study period, hence not reported herein. Thicker tumors
tend to result in more rapid demise and are likely to be
disproportionately represented among deaths occurring
shortly after diagnosis.
These trends are striking given elevated public awareness
and improved screening efforts aimed at detecting early,
thinner lesions over the past two decades. Beginning in 1985,
skin self examinations were increasingly promoted after the
development of the ABCD (asymmetry, border, color,
diameter) acronym (Heymann, 2007). At the same time,
dermatologist-led national screening and educational efforts
sponsored by the American Academy of Dermatology were
initiated, and have provided important educational messages
about sun protection and early detection (Geller et al., 2003).
Improved understanding of host risk factors has helped to
target screening efforts on high-risk groups, and the utiliza-
tion of new technologies such as dermoscopy has improved
the diagnostic accuracy (Geller et al., 2007).
Internationally, such interventions have had a larger
impact in some countries than in others. Population-based
studies from Scotland (Mackie et al., 2002; Murray et al.,
2005), France (Lipsker et al., 2007), Southern Germany
(Garbe et al., 2000), and Spain (Tejera-Vaquerizo et al.,
2008) demonstrate a substantial rise in the proportion of thin
tumors over the past two decades, whereas data from
Australia show proportions and trends comparable to those
seen in the United States (Garbe et al., 2000). For example,
Garbe et al. (2000) observed that the proportion of thin
(p0.75mm) tumors among cases of melanoma recorded by
the Queensland Melanoma register increased from 61.9 to
63.6% between 1986 and 1996. During this same period, the
proportion of thin (p0.75mm) melanomas among cases
recorded by the Central Malignant Melanoma Register of the
German Dermatological Society increased from 29.8 to
46.4%. Comparably, the proportion of thin (o1.5mm)
tumors recorded by the Scottish Melanoma Group increased
from 38 to 60% between 1985 and 2004 (Murray et al.,
2005). It seems that populations experiencing the greatest rise
in the proportion of thin tumors are those that began with
substantially lower proportions at baseline. Current screening
interventions and elevated public awareness are effective in
these areas but produce limited returns in areas with
longstanding screening and awareness campaigns.
Although current screening efforts have not had a
substantial effect on the early detection of thinner malignant
lesions in the United States, they have certainly had a
significant impact on the detection of non-invasive melano-
ma, the proportion of which doubled over the study period. A
similar rise in the incidence of melanoma in situ has been
reported in Australia (Coory et al., 2006), and in California
among an employed population undergoing increased
Table 3. Five-year cause-specific survival1 classified by tumor thickness, US 1988–2006
Five-year survival (95% CI)
Year of diagnosis p1mm 1.01–2mm 2.01–4mm 44mm
1988–1992 96.8 (96.4–97.2) 86.0 (84.3–87.5) 72.3 (69.4–75.0) 55.4 (50.7–59.8)
1993–1997 97.2 (96.9–97.5) 87.8 (86.6–89.0) 71.3 (69.0–73.4) 56.8 (53.3–60.1)
1998–2002 97.1 (96.9–97.4) 89.1 (88.2–89.9) 74.4 (72.8–76.0) 58.1 (55.5–60.5)
CI, confidence interval.
1Cause-specific survival is the probability of not dying from melanoma. It was calculated using the Kaplan–Meier method with cause of death defined by the
primary site, and the cause of death recorded on the death certificate.
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Figure 2. Median tumor thickness: US 1988–2006.
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Figure 3. Proportion of all melanomas that were melanoma in situ: US
1988–2006.
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screening (Schneider et al., 2008). There is considerable
uncertainty about the invasive potential of these lesions,
which reflects the dearth of study of their transformation. In a
survey of 1200 dermatologists, 83.6% considered melanoma
in situ to be a true malignancy, but 27.8% were unable to
estimate the proportion of untreated lesions that would
progress to invasive growth and 43.9% were unsure of the
metastatic potential (Charles et al., 2005). Unlike the trends
seen with cervical cancer screening, the incidence of
invasive melanoma continues to rise and mortality remains
stable despite large increases in the identification of non-
invasive lesions. This trend supports the argument that
increased screening efforts are leading to greater identifica-
tion of biologically inert lesions that have always been
present, but were not previously diagnosed as melanoma
(Burton and Armstrong, 1998).
Our results demonstrate a clear need for new screening
strategies. In addition, the expansion of current screening
techniques, such as the full body skin examination and
thorough skin self-examination are necessary. In a national
health survey of over 30,000 patients, the reported rate of full
body skin examination was only 21% (Santmyire et al.,
2001). Other studies found that the rate of thorough skin self-
examination ranged from 9 to 18% only (Weinstock et al.,
1999, 2004). Several shortcomings of the US healthcare
system provide barriers to expanded screening. Inequalities in
access to healthcare limit physician screening among patients
of low socioeconomic status and may result in increased
incidence of thick, late stage tumors and decreased survival
(Eide et al., 2009; Linos et al., 2009). Among the insured
patients, physician factors that inhibit screening include
shortages of primary care physicians, limited time for patient
encounters, lack of incentives for preventative care, and
absence of skin examination training (Moore et al., 2006).
Even with additional time and better training, preventative
strategies will remain underutilized without clear recommen-
dations from authoritative bodies backed by evidence
showing the benefits of early detection of skin cancer (Lee
and Weinstock, 2009).
Although anticipated comprehensive healthcare reform
may help to address some of these issues, rising incidence,
non-declining overall mortality and relatively unchanging
thickness distributions demand immediate action. Geller
et al. (2006) recently outlined a proposal for a targeted
national melanoma-screening program consisting of policy
changes, expanded public outreach, education of clinicians
and legislative advocacy. To justify such an undertaking,
studies demonstrating the benefits of population-wide screen-
ings are necessary and may be forthcoming (Koh, 2007;
Geller, 2009). One screening and educational program
initiated among employees of the Lawrence Livermore
National Laboratory in California resulted in a 69% reduction
in crude incidence of thick (40.75mm) tumors (Schneider
et al., 2008). Additional data from a large randomized
screening trial in Queensland, Australia, demonstrated high
specificity for full body skin examination (Aitken et al.,
2006a), and a significant rise in the number of full body skin
examinations among intervention groups (Aitken et al.,
2006b). Recently, investigators formed the Melanoma
Screening Group and have begun working towards the
creation of a similar melanoma early detection trial in the
United States (Geller, 2009).
In preparation for new screening modalities, it is important
to have a data collection system that can accurately measure
population-wide effects. Our study identifies several pro-
blems within SEER data that limit this ability. First, the
underreporting of tumor thickness, although improving,
remains high, especially among fatal cases. Second, ambi-
guity in thickness codes and inconsistencies in the reporting
of tumor thickness are present in SEER. We identified over
1,000 cases of malignant, invasive melanoma that were
recorded as having a thickness of 0, defined as ‘‘no mass; no
tumor found.’’ Similarly, several thousand cases of in situ
melanoma were recorded as having a non-zero thickness.
The upper limit of recording thickness in SEER is 9.90mm,
with no option for recording thickness of tumors greater than
this cutoff. These problems limit the analysis of melanoma
thickness trends and should be rectified. Additional limita-
tions of SEER data have been documented and include
absence of independent verification of diagnoses (Merlino
et al., 1997), lack of case detail, underregistration (Cockburn
et al., 2008) and delayed reporting (Clegg et al., 2002).
Our population-based study, the largest assessment to
date, provides comprehensive analysis of tumor thickness
trends in the United States and describes patterns among fatal
melanomas that have not been previously reported. These
data highlight the need for new and expanded melanoma
screening modalities and improvements in the collection and
recording of data used to measure their effectiveness.
MATERIALS AND METHODS
Data were obtained from 17 population-based cancer registries of
the SEER program of the US National Cancer Institute (SEER, 2008).
The study period (1988–2006) includes all years in which tumor
thickness was consistently recorded. Data from the original 9 SEER
registries were available for the entire study period. Four additional
registries (Los Angelos and San Jose, California; Alaska; and rural
Georgia) added data for the last 15 years of the study period, and
another four registries (Greater California excluding San Francisco,
Los Angeles and San Jose; Kentucky; Louisiana; and New Jersey)
provided data for the last 6 years of the period. Together, these
seventeen SEER registries represent approximately 26% of the US
population. For study purposes, cases of malignant melanoma were
defined as those with International Classification of Diseases for
Oncology (ICD-O) histological types melanoma not otherwise
specified (code 8720), nodular melanoma (code 8721), lentigo
maligna melanoma (code 8742), superficial spreading melanoma
(code 8743), acral lentiginous melanoma (code 8744), other
melanoma subcategories (codes 8777, 8723, 8730, 8740, 8741,
8745, 8746, 8761, 8770, 8771, 8772), ICD-O behavior type
malignant (code 3), and primary site of skin (codes 440–449). Tumor
thickness was stratified according to the American Joint Committee
on Cancer thickness categories (p1, 1.01–2, 2.01–4,44mm). Cases
of malignant melanoma with ‘‘no mass or tumor found’’ (extent of
disease code 0) were not included in the analysis (see last paragraph
of Results section for further information on inconsistencies
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observed). Fatal melanomas were defined as cases of malignant
melanoma diagnosed between 1988 and 2006, and who died by
2006, with melanoma recorded as the primary cause of death on
death certificate review. These deaths were identified in SEER by
cause of death to site recode (code 25010). Survival was calculated
with SEER*Stat using the Kaplan–Meier method. Cause-specific
survival is the probability of not dying from melanoma. Melanoma
in situ were identified by ICD-O behavior code in situ (code 2). Only
cases with unrecorded thickness (extent of disease code 999) or no
mass found (extent of disease code 0) were included in the analysis
of in situ cases (see last paragraph of Results section for additional
details). Data were analyzed using Stata SE version 8 (StataCorp,
College Station, TX). CI values were calculated using proportion tests
in Stata SE. Given the large sample size, all differences in proportions
were statistically significant (Po0.001) unless otherwise specified.
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